https://www.selleckchem.com/products/tween-80.html
2 to $34.6 million (10.9%), driven by 18 F-fluciclovine imaging agent and procedure costs. The cost per 'correct' diagnosis declined $30,673 (46.8%). When including subsequent 5-year patient management, the cost per 'correct' diagnosis declined $410,206 (49.2%). Conclusion 18 F-fluciclovine PET/CT imaging may improve the clinical management of men with recurrent PCa with minimal increase in healthcare spending. © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor Francis Group.Introduction and objective Vernal
Me gusta
Comentario
Compartir
